Blueprint Medicines Corp (NASDAQ:BPMC) — Market Cap & Net Worth
Market Cap & Net Worth: Blueprint Medicines Corp (BPMC)
Blueprint Medicines Corp (NASDAQ:BPMC) has a market capitalization of $8.36 Billion ($8.36 Billion) as of September 15, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2561 globally and #935 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Blueprint Medicines Corp's stock price $129.46 by its total outstanding shares 64582200 (64.58 Million). Also see balance sheet size of Blueprint Medicines Corp for a full breakdown of the balance sheet.
Blueprint Medicines Corp Market Cap History: 2015 to 2025
Blueprint Medicines Corp's market capitalization history from 2015 to 2025. Data shows growth from $1.70 Billion to $8.36 Billion (19.50% CAGR). Also see Blueprint Medicines Corp (BPMC) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Blueprint Medicines Corp is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.68 Trillion | 0.31% | #60 of 976 |
|
NASDAQ Composite
IXIC
|
$41.94 Trillion | 0.02% | #296 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.89 Trillion | 0.44% | #42 of 263 |
Weight: Blueprint Medicines Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Blueprint Medicines Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Blueprint Medicines Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Blueprint Medicines Corp stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
11.07x
Blueprint Medicines Corp's market cap is 11.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.70 Billion | $11.40 Million | -$52.77 Million | 149.22x | N/A |
| 2016 | $1.81 Billion | $27.77 Million | -$72.50 Million | 65.23x | N/A |
| 2017 | $4.87 Billion | $21.43 Million | -$148.12 Million | 227.30x | N/A |
| 2018 | $3.48 Billion | $44.52 Million | -$236.64 Million | 78.20x | N/A |
| 2019 | $5.17 Billion | $66.51 Million | -$328.70 Million | 77.79x | N/A |
| 2020 | $7.24 Billion | $793.74 Million | $313.88 Million | 9.13x | 23.08x |
| 2021 | $6.92 Billion | $180.08 Million | -$644.09 Million | 38.41x | N/A |
| 2022 | $2.83 Billion | $204.04 Million | -$557.52 Million | 13.87x | N/A |
| 2023 | $5.96 Billion | $249.38 Million | -$506.98 Million | 23.89x | N/A |
| 2024 | $5.63 Billion | $508.82 Million | -$67.09 Million | 11.07x | N/A |
Competitor Companies of BPMC by Market Capitalization
Companies near Blueprint Medicines Corp in the global market cap rankings as of September 15, 2026. Review how tangible is Blueprint Medicines Corp's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Blueprint Medicines Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #338 globally with a market cap of $80.28 Billion USD.
- CSL Ltd (AU:CSL): Ranked #463 globally with a market cap of $58.90 Billion USD ( AU$83.24 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $519.51 |
| #338 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.28 Billion | $793.74 |
| #463 | CSL Ltd | AU:CSL | $58.90 Billion | AU$171.57 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $146.69 |
Blueprint Medicines Corp Historical Marketcap From 2015 to 2025
Between 2015 and today, Blueprint Medicines Corp's market cap moved from $1.70 Billion to $ 8.36 Billion, with a yearly change of 19.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $8.36 Billion | +48.43% |
| 2024 | $5.63 Billion | -5.44% |
| 2023 | $5.96 Billion | +110.55% |
| 2022 | $2.83 Billion | -59.10% |
| 2021 | $6.92 Billion | -4.49% |
| 2020 | $7.24 Billion | +40.00% |
| 2019 | $5.17 Billion | +48.60% |
| 2018 | $3.48 Billion | -28.51% |
| 2017 | $4.87 Billion | +168.84% |
| 2016 | $1.81 Billion | +6.49% |
| 2015 | $1.70 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 16th, 2026 the market cap of Blueprint Medicines Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.36 Billion USD |
| MoneyControl | $8.36 Billion USD |
| MarketWatch | $8.36 Billion USD |
| marketcap.company | $8.36 Billion USD |
| Reuters | $8.36 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast … Read more